ClinicalTrials.gg
CompletedNCT01515748PRODIGYUpdated Dec 13, 2023Results posted

Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer

A Phase 3 interventional study of Docetaxel (XRP6976) and Oxaliplatin (SR96669) in Gastric Cancer, sponsored by Sanofi. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-12-13.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
530
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 103 studies testing docetaxel in Stomach Neoplasms — 9 open to participants now, 13 under way, 5 of them phase 3. Docetaxel · Stomach Neoplasms.

Enrollment
4th of 99
530 · median 50
Started
2011
with 2 others
Phase 3
10 of 103
4 open now
Registered
60th of 103
by date
Lead sponsor
6 of 103
Sanofi

Among the 103 studies testing docetaxel in Stomach Neoplasms, this one is the 4th largest by enrollment of the 99 interventional ones that give a count, is one of 3 that started in 2011, is one of 10 in phase 3, and was the 60th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

9 of the 103 studies testing docetaxel in Stomach Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies testing docetaxel in Stomach Neoplasms, or all of them as a file.
02

Study summary

Primary Objective:

  • To compare the 3-year progression free survival (PFS) in the two treatment arms.

Secondary Objectives:

  • Overall survival (OS).
  • Postoperative pathological stage and R0 (complete) resection rate.
  • Safety: Toxicities associated with neoadjuvant chemotherapy, surgery, morbidity/mortality, toxicity of adjuvant chemotherapy.
Read the detailed description

Participants in the neoadjuvant chemotherapy arm were treated for 3 cycles (1 cycle is 21 days) before surgery and treated for a year with S-1. Participants in the adjuvant chemotherapy arm underwent surgery and were treated for a year with S-1. All participants were followed during and after the study treatment until death or disease progression, whichever comes first.

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with new confirmed, newly diagnosed, localized gastric or gastro-oesophageal adenocarcinoma, that is considered resectable.
  • Participants with clinical stage (T2-3/N(+), T4/N(+/-):N positive means greater than or equal to [>=] 8 in hour axis).
  • Signed .

Exclusion criteria

Exclusion criteria:

  • Aged less than (\<) 20 years or >= 76 years. Performance status >=2 in (ECOG) scale
  • The participants who had the history of other within the last five years except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix which had been already successfully treated.
  • Previous surgery on neoplasm of stomach.
  • Participants who did not completely recovered from surgery.
  • Distant (M1) to other organs including distant nodal groups (retropancreatic, para-aortic, portal, retroperitoneal, mesenteric node). severe/unstable angina, coronary artery bypass graft, congestive heart failure, within 6 months prior to enrollment in the study.
  • Any previous palliative, or neoadjuvant chemotherapy and/or radiotherapy and/or immunotherapy, for the currently treated gastric cancer.
  • Participants with active infection or sepsis.
  • Intolerance of oral taking or malabsorption: lack of physical integrity of the upper gastrointestinal tract or those who have malabsorption syndrome likely to influence absorption of S-1. Ileus, chronic inflammatory intestinal disease or extensive resection of the small intestine and other disorders which limit drug resorption. This includes gastric dumping syndrome, indications of accelerated passage through the small intestine and indications of resorption disorders after intestinal surgery.
  • Greater than or equal to grade 2 severe tumour haemorrhage.
  • Simultaneous participation in another study, or participation in another study within 4 weeks of commencement of this study.
  • Pregnant or lactating participants.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
530 participants (actual)

Study arms

  • Other
    Surgery + Adjuvant Chemotherapy (SC)

    Participants underwent surgery within 2 weeks after randomization followed by adjuvant chemotherapy with S-1 \[(Gimeracil) + Oxo (Oteracil)\] 40 milligrams per square meter (mg/m\^2) administered orally twice daily, from Day 1 to 28 of each cycle for 1 year, and were followed-up after End-of-Treatment (EOT) until disease progression or death or study cut-off date, whichever comes first (maximum duration: up to 10 years).

    Drug: S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)

  • Experimental
    Neoadjuvant Chemotherapy +Surgery +Adjuvant chemotherapy (CSC)

    Participants received neo-adjuvant chemotherapy with Docetaxel 50 mg/m\^2 intravenously (IV) for greater than or equal to (\>=)1 hour (hr) on Day 1 of each treatment cycle plus Oxaliplatin 100 mg/m\^2 IV for \>=2 hr on Day 1 of each treatment cycle plus S-1 \[(Gimeracil) + Oxo (Oteracil)\] 40 mg/m\^2 administered orally twice daily from Day 1 to 14, of each treatment cycle followed by surgery approximately 1-3 weeks after completion of neo-adjuvant chemotherapy and adjuvant chemotherapy with S-1 \[(Gimeracil) + Oxo (Oteracil)\] 40 mg/m\^2 administered orally twice daily, from Day 1 to 28 of each cycle for 1 year, and were followed-up after EOT until disease progression or death or study cut-off date, whichever comes first (maximum duration: up to 10 years).

    Drug: Docetaxel (XRP6976) · Drug: Oxaliplatin (SR96669) · Drug: S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)

Interventions

  • Pharmaceutical form:solution for infusion Route of administration: intravenous

  • Pharmaceutical form:solution for infusion Route of administration: intravenous

  • DrugS-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)

    Drug page: Gimeracil

    Pharmaceutical form:Tablet Route of administration: Oral

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With 3-Year Progression-Free Survival (PFS), as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)1.1

    PFS was defined as the time from randomization to objective tumor progression, or recurrence or death. Progressive disease (PD) was defined as follows: 1) In Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) Arm, PD was determined according to the RECIST 1.1 Criteria during the neo-adjuvant chemotherapy period; 2) Irrespective of curative resection, if an intraoperative distant metastasis was observed or a distant metastasis was reported from pathology, it was considered PD; 3) If residual cancer cells were visually identified at the resection margin during surgery but could not be completely resected (R2), it was considered PD; 4) If residual cancer cells were finally confirmed at the resection margin during postoperative histology (R1), it was considered PD; 5) In case of finding a recurrence/distant metastasis or a new lesion during follow-up after R0 complete resection, it was defined as the first tumor assessment date when it was observed.

    Time frame: 3 years

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from randomization to death due to any cause. Analyzed using Kaplan-Meier method.

    Time frame: From randomization to date of death due to any cause (maximum duration: up to 10 years)

  2. Number of Participants With Post-Operative Pathological Stage Response

    TNM pathological stage was determined according to standardized histopathology and the American Joint Committee on Cancer (AJCC) staging system 7th Edition (Stages 0,IA,IB,IIA,IIB,IIIA,IIIB,IIIC and IV). Stage 0=carcinoma in situ with no metastatic potential; Stage IA=T1N0M0; Stage IB=T2N0M0,T1N1M0; Stage IIA=T3N0M0,T2N1M0,T1N2M0;Stage IIB=T4aN0M0,T3N1M0,T2N2M0,T1N3M0;Stage IIIA=T4aN1M0,T3N2M0,T2N3M0;Stage IIIB=T4bN0-1M0,T4aN2M0,T3N3M0;Stage IIIC=T4bN2-3M0, T4aN3M0 and Stage IV= distant metastases (M1) at diagnosis; where "T" denotes "tumor size" where T1: tumor invades lamina propria, muscularis mucosae, or submucosa; T2: invades muscularis propria; T3: invasion of subserosa; T4: T4a: penetrate serosa (visceral peritoneum) T4b: invade adjacent tissue and " N" denotes "nodes affected" where N1:1-2 positive lymph nodes; N2:3-6 positive lymph nodes; N3: 7 or more positive lymph nodes and "M" denotes metastases where M0: no distant metastases. Higher stages indicates worse outcome.

    Time frame: Up to 10 years

  3. Percentage of Participants With R0 Resection

    Tumor condition was explained according to the Residual Tumor (R) Classification: R0; No residual cancer (negative cross-section), R1; Microscopically observed residual cancer (positive cross-section), R2; Macroscopically observed residual cancer.

    Time frame: Up to 10 years

  4. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    TEAEs were defined as adverse events (AE) that appeared or worsened during the treatment period (up to 30 days after the last dose of the investigational product). SAE was an AE or adverse drug reaction at any dose of the investigational product that corresponded to one of the following: resulting in death or is life threatening; requiring in-patient hospitalization or prolongation of existing hospitalization; resulting in persistent or significant disability of dysfunction; resulting in congenital anomaly or birth defect; important medical event.

    Time frame: From randomization up to 30 days after last dose of study drug (maximum duration: up to 10 years)

  5. Number of Participants With Shift of Laboratory Parameters (Hematology) From Baseline Grade to Worst National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade >=3

    NCI-CTCAE version 4.03 was used to determine Grade(Gr),where Gr refers to severity of AE:Gr 1:mild; asymptomatic/mild symptoms; Gr 2:moderate;minimal; Gr 3:severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Hemoglobin(Hb)(Anemia) were based on Gr1:\<lower limit of normal (LLN)-10.0g/dL; Gr2:\<10.0-8.0g/dL; Gr3:\<8.0g/dL; Gr4:life-threatening consequences;Gr5:death. Hb increased:Gr 1:increase(incr.) in \>0-2g/dL above upper limit of normal(ULN);Gr2: incr. in \>2-4g/dL above ULN; Gr3:incr. in \>4gm/dL above ULN. White blood cell (WBC) decreased: Gr1:\<LLN - 3000/mm\^3;Gr2: \<3000-2000/mm\^3; Gr3:\<2000-1000/mm\^3;Gr4:\<1000/mm\^3. WBC (Leukocytosis):Gr3:\>100,000/mm\^3, Gr4:clinical manifestations of leucostasis;Gr5:Death. Abnormal Neutrophil count (ANC):- Gr1:\<LLN-1500/mm\^3;Gr2:\<1500-1000/mm\^3; Gr3: \<1000-500/mm\^3; Gr4:\<500/mm\^3. Platelet count decreased: Gr1:\<LLN-75,000/mm\^3;Gr2:\<75,000-50,000/mm\^3;Gr3:\<50,000-25,000/mm\^3;Gr4:\<25,000/mm\^3.

    Time frame: From Baseline up to 30 days after last dose of study drug (maximum duration: up to 10 years)

  6. Number of Participants With Shift of Laboratory Parameters (Sodium and Potassium Levels) From Baseline Grade to Worst NCI-CTCAE Grade >=3

    NCI-CTCAE version 4.03 was used to determine Gr,where Gr refers to severity of AE: Gr 1: mild; asymptomatic/mild symptoms; Gr 2: moderate; minimal; Gr 3:severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Sodium (Hyponatremia) were based on Gr1: \<LLN-130 mmol/L; Gr3: \<130-120 mmol/L; Gr4: \<120 mmol/L; life-threatening consequences; Gr5: death. Sodium (Hypernatremia):Gr 1: \>ULN-150 mmol/L; Gr2: \>150-155 mmol/L; Gr3:\>155-160 mmol/L;hospitalization; Gr4: \>160 mmol/L; life-threatening consequences; Gr5: Death. Potassium (Hypokalemia): Gr 1: \<LLN-3.0 mmol/L; Gr2: \<LLN-3.0 mmol/L; symptomatic; intervention indicated; Gr3: \<3.0-2.5 mmol/L; hospitalization indicated; Gr4: \<2.5 mmol/L; life-threatening consequences; Gr5: Death; Potassium(Hyperkalemia): Gr 1: \>ULN-5.5 mmol/L; Gr2: \>5.5-6.0 mmol/L; Gr3: \>6.0-7.0 mmol/L; hospitalization indicated; Gr4: \>7.0 mmol/L; life-threatening consequences; Gr5: Death.

    Time frame: From Baseline up to 30 days after last dose of study drug (maximum duration: up to 10 years)

  7. Number of Participants With Shift of Laboratory Parameters (Calcium, Creatinine and Albumin Levels) From Baseline Grade to Worst NCI-CTCAE Grade >=3

    NCI-CTCAE version 4.03 was used to determine Gr,where Gr refers to severity of AE:Gr 1:mild; asymptomatic/mild symptoms; Gr 2:moderate;minimal; Gr 3:severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Calcium(Hypocalcemia) were based on Gr1: Corrected serum calcium of \<LLN-8.0 mg/dL; Gr2: Corrected serum calcium of \<8.0-7.0 mg/dL; Gr3: Corrected serum calcium of \<7.0-6.0 mg/dL ; Gr4: Corrected serum calcium of \<6.0 mg/dL;Gr5:death. Calcium(Hypercalcemia):Gr 1: Corrected serum calcium of \>ULN -11.5 mg/dL; Gr2: Corrected serum calcium of \>11.5-12.5 mg/dL; Gr3: Corrected serum calcium of \>12.5-13.5 mg/dL; Gr4: Corrected serum calcium of \>13.5 mg/dL;Gr5:Death. Creatinine increased: Gr 1: \>1-1.5\*baseline; \>ULN-1.5\*ULN; Gr2: \>1.5-3.0\*baseline; \>1.5-3.0\*ULN; Gr3: \>3.0 baseline; \>3.0-6.0\*ULN; Gr4: \>6.0 x ULN. Albumin(Hypoalbuminemia): Gr 1: \<LLN-3 g/dL; Gr2: \<3-2 g/dL; Gr3: \<2 g/dL; Gr4:life-threatening consequences;Gr5:Death.

    Time frame: From Baseline up to 30 days after last dose of study drug (maximum duration: up to 10 years)

  8. Number of Participants With Shift of Laboratory Parameters (Aspartate Aminotransferase, Alanine Aminotransferase,Blood Bilirubin,Alkaline Phosphatase and Glucose Levels) From Baseline Grade to Worst NCI-CTCAE Grade >=3

    NCI-CTCAE version 4.03 was used to determine Gr, where Gr refers to severity of AE: Gr 1:mild; asymptomatic/mild symptoms; Gr 2:moderate; minimal; Gr 3:severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Aspartate and alanine aminotransferase increased were based on Gr1: \>ULN-3.0\*ULN; Gr2: \>3.0-5.0\*ULN; Gr3: \>5.0-20.0\*ULN; Gr4: \>20.0\*ULN. Blood bilirubin increased: Gr1: \>ULN-1.5\*ULN; Gr2 \>1.5-3.0\*ULN; Gr3: \>3.0-10.0\*ULN; Gr4: \>10.0\*ULN. Alkaline phosphatase increased: Gr1: \>ULN-2.5\*ULN; Gr2: \>2.5-5.0\*ULN; Gr3: \>5.0-20.0\*ULN; Gr4: \>20.0\*ULN. Glucose (Hypoglycemia): Gr 1: \<LLN-55 mg/dL; Gr2: \<55-40 mg/dL;Gr3: \<40-30 mg/dL; Gr4: \<30 mg/dL; Gr5:Death. Glucose (Hyperglycemia): Gr 1: Fasting glucose value \>ULN-160 mg/dL; Gr2: Fasting glucose value \>160-250 mg/dL; Gr3: \>250-500 mg/dL; Gr4: \>500 mg/dL; Gr5: Death.

    Time frame: From Baseline up to 30 days after last dose of study drug (maximum duration: up to 10 years)

  9. Number of Participants With Shift of Laboratory Parameters (Creatinine Clearance [Chronic Kidney Disease]) From Baseline Grade to Worst NCI-CTCAE Grade >=3

    NCI-CTCAE version 4.03 was used to determine Gr, where Gr refers to severity of AE: Gr 1: mild; asymptomatic/mild symptoms; Gr 2: moderate; minimal; Gr 3: severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Creatinine Clearance(Chronic kidney disease) were based on: Gr 1: estimated glomerular filtration rate (eGFR) or creatinine clearance (CrCl) \<LLN-60ml/min/1.73 m\^2; Gr2: eGFR or CrCl 59-30 ml/min/1.73 m\^2; Gr3: eGFR or CrCl 29-15 ml/min/1.73 m\^2; Gr4: eGFR or CrCl \<15 ml/min/1.73 m\^2; Gr5: Death.

    Time frame: From Baseline up to 30 days after last dose of study drug (maximum duration: up to 10 years)

07

Results

Posted Mar 2, 2020

Participant flow

The study was conducted at 18 sites in Korea. A total of 693 participants were screened between 30 December 2011 to 02 January 2019, of which, 163 were screen failures. Screen failures were mainly due to inclusion criteria not met.

Participant flow — Overall Study
MilestoneSurgery + Adjuvant Chemotherapy (SC)Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)
Started264266
Treated195241
Completed225211
Not completed3955
Withdrew: Withdrawal by subject3241
Withdrew: Lost to follow-up24
Withdrew: Other than specified above510

Outcome measures

PrimaryPercentage of Participants With 3-Year Progression-Free Survival (PFS), as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)1.1

PFS was defined as the time from randomization to objective tumor progression, or recurrence or death. Progressive disease (PD) was defined as follows: 1) In Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) Arm, PD was determined according to the RECIST 1.1 Criteria during the neo-adjuvant chemotherapy period; 2) Irrespective of curative resection, if an intraoperative distant metastasis was observed or a distant metastasis was reported from pathology, it was considered PD; 3) If residual cancer cells were visually identified at the resection margin during surgery but could not be completely resected (R2), it was considered PD; 4) If residual cancer cells were finally confirmed at the resection margin during postoperative histology (R1), it was considered PD; 5) In case of finding a recurrence/distant metastasis or a new lesion during follow-up after R0 complete resection, it was defined as the first tumor assessment date when it was observed.

Time frame:
3 years
Reported as:
Number · percentage of participants
Percentage of Participants With 3-Year Progression-Free Survival (PFS), as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)1.1
percentage of participantsSurgery + Adjuvant Chemotherapy (SC)Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)
Percentage of Participants With 3-Year Progression-Free Survival (PFS), as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)1.160.24 (53.55 to 66.28)66.82 (60.13 to 72.65)
Statistical analysis
  • Surgery + Adjuvant Chemotherapy (SC) vs Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) · Stratified Log Rank · p = 0.0152 (Threshold for statistical significance at 0.049.)
SecondaryOverall Survival (OS)

OS was defined as the time from randomization to death due to any cause. Analyzed using Kaplan-Meier method.

Time frame:
From randomization to date of death due to any cause (maximum duration: up to 10 years)
Reported as:
Median · months
Overall Survival (OS)
monthsSurgery + Adjuvant Chemotherapy (SC)Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
SecondaryNumber of Participants With Post-Operative Pathological Stage Response

TNM pathological stage was determined according to standardized histopathology and the American Joint Committee on Cancer (AJCC) staging system 7th Edition (Stages 0,IA,IB,IIA,IIB,IIIA,IIIB,IIIC and IV). Stage 0=carcinoma in situ with no metastatic potential; Stage IA=T1N0M0; Stage IB=T2N0M0,T1N1M0; Stage IIA=T3N0M0,T2N1M0,T1N2M0;Stage IIB=T4aN0M0,T3N1M0,T2N2M0,T1N3M0;Stage IIIA=T4aN1M0,T3N2M0,T2N3M0;Stage IIIB=T4bN0-1M0,T4aN2M0,T3N3M0;Stage IIIC=T4bN2-3M0, T4aN3M0 and Stage IV= distant metastases (M1) at diagnosis; where "T" denotes "tumor size" where T1: tumor invades lamina propria, muscularis mucosae, or submucosa; T2: invades muscularis propria; T3: invasion of subserosa; T4: T4a: penetrate serosa (visceral peritoneum) T4b: invade adjacent tissue and " N" denotes "nodes affected" where N1:1-2 positive lymph nodes; N2:3-6 positive lymph nodes; N3: 7 or more positive lymph nodes and "M" denotes metastases where M0: no distant metastases. Higher stages indicates worse outcome.

Time frame:
Up to 10 years
Reported as:
Count of participants · Participants
Number of Participants With Post-Operative Pathological Stage Response
ParticipantsSurgery + Adjuvant Chemotherapy (SC)Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)
Stage 0023
Stage IA932
Stage IB1823
Stage IIA3047
Stage IIB2536
Stage IIIA3518
Stage IIIB4924
Stage IIIC4614
Stage IV345
SecondaryPercentage of Participants With R0 Resection

Tumor condition was explained according to the Residual Tumor (R) Classification: R0; No residual cancer (negative cross-section), R1; Microscopically observed residual cancer (positive cross-section), R2; Macroscopically observed residual cancer.

Time frame:
Up to 10 years
Reported as:
Number · percentage of participants
Percentage of Participants With R0 Resection
percentage of participantsSurgery + Adjuvant Chemotherapy (SC)Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)
Percentage of Participants With R0 Resection83.74 (79.13 to 88.35)95.50 (92.77 to 98.22)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

TEAEs were defined as adverse events (AE) that appeared or worsened during the treatment period (up to 30 days after the last dose of the investigational product). SAE was an AE or adverse drug reaction at any dose of the investigational product that corresponded to one of the following: resulting in death or is life threatening; requiring in-patient hospitalization or prolongation of existing hospitalization; resulting in persistent or significant disability of dysfunction; resulting in congenital anomaly or birth defect; important medical event.

Time frame:
From randomization up to 30 days after last dose of study drug (maximum duration: up to 10 years)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsSurgery + Adjuvant Chemotherapy (SC)Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)
Any TEAE190237
Any treatment emergent SAE57102
TEAEs leading to permanent discontinuation1125
SecondaryNumber of Participants With Shift of Laboratory Parameters (Hematology) From Baseline Grade to Worst National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade >=3

NCI-CTCAE version 4.03 was used to determine Grade(Gr),where Gr refers to severity of AE:Gr 1:mild; asymptomatic/mild symptoms; Gr 2:moderate;minimal; Gr 3:severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Hemoglobin(Hb)(Anemia) were based on Gr1:\<lower limit of normal (LLN)-10.0g/dL; Gr2:\<10.0-8.0g/dL; Gr3:\<8.0g/dL; Gr4:life-threatening consequences;Gr5:death. Hb increased:Gr 1:increase(incr.) in \>0-2g/dL above upper limit of normal(ULN);Gr2: incr. in \>2-4g/dL above ULN; Gr3:incr. in \>4gm/dL above ULN. White blood cell (WBC) decreased: Gr1:\<LLN - 3000/mm\^3;Gr2: \<3000-2000/mm\^3; Gr3:\<2000-1000/mm\^3;Gr4:\<1000/mm\^3. WBC (Leukocytosis):Gr3:\>100,000/mm\^3, Gr4:clinical manifestations of leucostasis;Gr5:Death. Abnormal Neutrophil count (ANC):- Gr1:\<LLN-1500/mm\^3;Gr2:\<1500-1000/mm\^3; Gr3: \<1000-500/mm\^3; Gr4:\<500/mm\^3. Platelet count decreased: Gr1:\<LLN-75,000/mm\^3;Gr2:\<75,000-50,000/mm\^3;Gr3:\<50,000-25,000/mm\^3;Gr4:\<25,000/mm\^3.

Time frame:
From Baseline up to 30 days after last dose of study drug (maximum duration: up to 10 years)
Reported as:
Count of participants · Participants
Number of Participants With Shift of Laboratory Parameters (Hematology) From Baseline Grade to Worst National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade >=3
ParticipantsSurgery + Adjuvant Chemotherapy (SC)Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)
Hb(Anemia) Gr 0 at Baseline to Gr >=300
Hb(Anemia) Gr 1 at Baseline to Gr >=304
Hb(Anemia) Gr 2 at Baseline to Gr >=311
Hb(Anemia) Gr 3 at Baseline to Gr >=300
Hb(Anemia) Gr 4 at Baseline to Gr >=300
Hb(Anemia) Gr 5 at Baseline to Gr >=300
Hb increased Gr 0 at Baseline to Gr >=300
Hb increased Gr 1 at Baseline to Gr >=300
Hb increased Gr 2 at Baseline to Gr >=300
Hb increased Gr 3 at Baseline to Gr >=300
Hb increased Gr 4 at Baseline to Gr >=300
Hb increased Gr 5 at Baseline to Gr >=300
WBC decreased Gr 0 at Baseline to Gr >=318
WBC decreased Gr 1 at Baseline to Gr >=301
WBC decreased Gr 2 at Baseline to Gr >=300
WBC decreased Gr 3 at Baseline to Gr >=300
WBC decreased Gr 4 at Baseline to Gr >=300
WBC decreased Gr 5 at Baseline to Gr >=300
WBC (Leukocytosis) Gr 0 at Baseline to Gr >=301
WBC (Leukocytosis) Gr 1 at Baseline to Gr >=300
WBC (Leukocytosis) Gr 2 at Baseline to Gr >=300
WBC (Leukocytosis) Gr 3 at Baseline to Gr >=300
WBC (Leukocytosis) Gr 4 at Baseline to Gr >=300
WBC (Leukocytosis) Gr 5 at Baseline to Gr >=300
ANC Gr 0 at Baseline to Gr >=31440
ANC Gr 1 at Baseline to Gr >=300
ANC Gr 2 at Baseline to Gr >=310
ANC Gr 3 at Baseline to Gr >=300
ANC Gr 4 at Baseline to Gr >=300
ANC Gr 5 at Baseline to Gr >=300
Platelet count decreased Gr0 at Baseline to Gr >=305
Platelet count decreased Gr1 at Baseline to Gr >=300
Platelet count decreased Gr2 at Baseline to Gr >=300
Platelet count decreased Gr3 at Baseline to Gr >=300
Platelet count decreased Gr4 at Baseline to Gr >=300
Platelet count decreased Gr5 at Baseline to Gr >=300
SecondaryNumber of Participants With Shift of Laboratory Parameters (Sodium and Potassium Levels) From Baseline Grade to Worst NCI-CTCAE Grade >=3

NCI-CTCAE version 4.03 was used to determine Gr,where Gr refers to severity of AE: Gr 1: mild; asymptomatic/mild symptoms; Gr 2: moderate; minimal; Gr 3:severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Sodium (Hyponatremia) were based on Gr1: \<LLN-130 mmol/L; Gr3: \<130-120 mmol/L; Gr4: \<120 mmol/L; life-threatening consequences; Gr5: death. Sodium (Hypernatremia):Gr 1: \>ULN-150 mmol/L; Gr2: \>150-155 mmol/L; Gr3:\>155-160 mmol/L;hospitalization; Gr4: \>160 mmol/L; life-threatening consequences; Gr5: Death. Potassium (Hypokalemia): Gr 1: \<LLN-3.0 mmol/L; Gr2: \<LLN-3.0 mmol/L; symptomatic; intervention indicated; Gr3: \<3.0-2.5 mmol/L; hospitalization indicated; Gr4: \<2.5 mmol/L; life-threatening consequences; Gr5: Death; Potassium(Hyperkalemia): Gr 1: \>ULN-5.5 mmol/L; Gr2: \>5.5-6.0 mmol/L; Gr3: \>6.0-7.0 mmol/L; hospitalization indicated; Gr4: \>7.0 mmol/L; life-threatening consequences; Gr5: Death.

Time frame:
From Baseline up to 30 days after last dose of study drug (maximum duration: up to 10 years)
Reported as:
Count of participants · Participants
Number of Participants With Shift of Laboratory Parameters (Sodium and Potassium Levels) From Baseline Grade to Worst NCI-CTCAE Grade >=3
ParticipantsSurgery + Adjuvant Chemotherapy (SC)Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)
Hyponatremia Gr 0 at Baseline to Gr >=317
Hyponatremia Gr 1 at Baseline to Gr >=300
Hyponatremia Gr 2 at Baseline to Gr >=300
Hyponatremia Gr 3 at Baseline to Gr >=301
Hyponatremia Gr 4 at Baseline to Gr >=300
Hyponatremia Gr 5 at Baseline to Gr >=300
Hypernatremia Gr 0 at Baseline to Gr >=300
Hypernatremia Gr 1 at Baseline to Gr >=300
Hypernatremia Gr 2 at Baseline to Gr >=300
Hypernatremia Gr 3 at Baseline to Gr >=300
Hypernatremia Gr 4 at Baseline to Gr >=300
Hypernatremia Gr 5 at Baseline to Gr >=300
Hypokalemia Gr 0 at Baseline to Gr >=312
Hypokalemia Gr 1 at Baseline to Gr >=311
Hypokalemia Gr 2 at Baseline to Gr >=300
Hypokalemia Gr 3 at Baseline to Gr >=300
Hypokalemia Gr 4 at Baseline to Gr >=300
Hypokalemia Gr 5 at Baseline to Gr >=300
Hyperkalemia Gr 0 at Baseline to Gr >=314
Hyperkalemia Gr 1 at Baseline to Gr >=300
Hyperkalemia Gr 2 at Baseline to Gr >=300
Hyperkalemia Gr 3 at Baseline to Gr >=300
Hyperkalemia Gr 4 at Baseline to Gr >=300
Hyperkalemia Gr 5 at Baseline to Gr >=300
SecondaryNumber of Participants With Shift of Laboratory Parameters (Calcium, Creatinine and Albumin Levels) From Baseline Grade to Worst NCI-CTCAE Grade >=3

NCI-CTCAE version 4.03 was used to determine Gr,where Gr refers to severity of AE:Gr 1:mild; asymptomatic/mild symptoms; Gr 2:moderate;minimal; Gr 3:severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Calcium(Hypocalcemia) were based on Gr1: Corrected serum calcium of \<LLN-8.0 mg/dL; Gr2: Corrected serum calcium of \<8.0-7.0 mg/dL; Gr3: Corrected serum calcium of \<7.0-6.0 mg/dL ; Gr4: Corrected serum calcium of \<6.0 mg/dL;Gr5:death. Calcium(Hypercalcemia):Gr 1: Corrected serum calcium of \>ULN -11.5 mg/dL; Gr2: Corrected serum calcium of \>11.5-12.5 mg/dL; Gr3: Corrected serum calcium of \>12.5-13.5 mg/dL; Gr4: Corrected serum calcium of \>13.5 mg/dL;Gr5:Death. Creatinine increased: Gr 1: \>1-1.5\*baseline; \>ULN-1.5\*ULN; Gr2: \>1.5-3.0\*baseline; \>1.5-3.0\*ULN; Gr3: \>3.0 baseline; \>3.0-6.0\*ULN; Gr4: \>6.0 x ULN. Albumin(Hypoalbuminemia): Gr 1: \<LLN-3 g/dL; Gr2: \<3-2 g/dL; Gr3: \<2 g/dL; Gr4:life-threatening consequences;Gr5:Death.

Time frame:
From Baseline up to 30 days after last dose of study drug (maximum duration: up to 10 years)
Reported as:
Count of participants · Participants
Number of Participants With Shift of Laboratory Parameters (Calcium, Creatinine and Albumin Levels) From Baseline Grade to Worst NCI-CTCAE Grade >=3
ParticipantsSurgery + Adjuvant Chemotherapy (SC)Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)
Hypocalcemia Gr 0 at Baseline to Gr >=310
Hypocalcemia Gr 1 at Baseline to Gr >=300
Hypocalcemia Gr 2 at Baseline to Gr >=300
Hypocalcemia Gr 3 at Baseline to Gr >=300
Hypocalcemia Gr 4 at Baseline to Gr >=300
Hypocalcemia Gr 5 at Baseline to Gr >=300
Hypercalcemia Gr 0 at Baseline to Gr >=311
Hypercalcemia Gr 1 at Baseline to Gr >=300
Hypercalcemia Gr 2 at Baseline to Gr >=300
Hypercalcemia Gr 3 at Baseline to Gr >=300
Hypercalcemia Gr 4 at Baseline to Gr >=300
Hypercalcemia Gr 5 at Baseline to Gr >=300
Creatinine increased Gr 0 at Baseline to Gr >=348
Creatinine increased Gr 1 at Baseline to Gr >=300
Creatinine increased Gr 2 at Baseline to Gr >=300
Creatinine increased Gr 3 at Baseline to Gr >=300
Creatinine increased Gr 4 at Baseline to Gr >=300
Creatinine increased Gr 5 at Baseline to Gr >=300
Hypoalbuminemia Gr 0 at Baseline to Gr >=312
Hypoalbuminemia Gr 1 at Baseline to Gr >=300
Hypoalbuminemia Gr 2 at Baseline to Gr >=300
Hypoalbuminemia Gr 3 at Baseline to Gr >=300
Hypoalbuminemia Gr 4 at Baseline to Gr >=300
Hypoalbuminemia Gr 5 at Baseline to Gr >=300
SecondaryNumber of Participants With Shift of Laboratory Parameters (Aspartate Aminotransferase, Alanine Aminotransferase,Blood Bilirubin,Alkaline Phosphatase and Glucose Levels) From Baseline Grade to Worst NCI-CTCAE Grade >=3

NCI-CTCAE version 4.03 was used to determine Gr, where Gr refers to severity of AE: Gr 1:mild; asymptomatic/mild symptoms; Gr 2:moderate; minimal; Gr 3:severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Aspartate and alanine aminotransferase increased were based on Gr1: \>ULN-3.0\*ULN; Gr2: \>3.0-5.0\*ULN; Gr3: \>5.0-20.0\*ULN; Gr4: \>20.0\*ULN. Blood bilirubin increased: Gr1: \>ULN-1.5\*ULN; Gr2 \>1.5-3.0\*ULN; Gr3: \>3.0-10.0\*ULN; Gr4: \>10.0\*ULN. Alkaline phosphatase increased: Gr1: \>ULN-2.5\*ULN; Gr2: \>2.5-5.0\*ULN; Gr3: \>5.0-20.0\*ULN; Gr4: \>20.0\*ULN. Glucose (Hypoglycemia): Gr 1: \<LLN-55 mg/dL; Gr2: \<55-40 mg/dL;Gr3: \<40-30 mg/dL; Gr4: \<30 mg/dL; Gr5:Death. Glucose (Hyperglycemia): Gr 1: Fasting glucose value \>ULN-160 mg/dL; Gr2: Fasting glucose value \>160-250 mg/dL; Gr3: \>250-500 mg/dL; Gr4: \>500 mg/dL; Gr5: Death.

Time frame:
From Baseline up to 30 days after last dose of study drug (maximum duration: up to 10 years)
Reported as:
Count of participants · Participants
Number of Participants With Shift of Laboratory Parameters (Aspartate Aminotransferase, Alanine Aminotransferase,Blood Bilirubin,Alkaline Phosphatase and Glucose Levels) From Baseline Grade to Worst NCI-CTCAE Grade >=3
ParticipantsSurgery + Adjuvant Chemotherapy (SC)Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)
Aspartate aminotransferase Gr0 at Baseline toGr>=311
Aspartate aminotransferase Gr1 at Baseline toGr>=300
Aspartate aminotransferase Gr2 at Baseline toGr>=300
Aspartate aminotransferase Gr3 at Baseline toGr>=300
Aspartate aminotransferase Gr4 at Baseline toGr>=300
Aspartate aminotransferase Gr5 at Baseline toGr>=300
Alanine aminotransferase Gr0 at Baseline to Gr >=301
Alanine aminotransferase Gr1 at Baseline to Gr >=300
Alanine aminotransferase Gr2 at Baseline to Gr >=300
Alanine aminotransferase Gr3 at Baseline to Gr >=300
Alanine aminotransferase Gr4 at Baseline to Gr >=300
Alanine aminotransferase Gr5 at Baseline to Gr >=300
Bilirubin increased Gr 0 at Baseline to Gr >=324
Bilirubin increased Gr 1 at Baseline to Gr >=310
Bilirubin increased Gr 2 at Baseline to Gr >=310
Bilirubin increased Gr 3 at Baseline to Gr >=300
Bilirubin increased Gr 4 at Baseline to Gr >=300
Bilirubin increased Gr 5 at Baseline to Gr >=300
Alkaline phosphatase Gr 0 at Baseline to Gr >=330
Alkaline phosphatase Gr 1 at Baseline to Gr >=300
Alkaline phosphatase Gr 2 at Baseline to Gr >=300
Alkaline phosphatase Gr 3 at Baseline to Gr >=300
Alkaline phosphatase Gr 4 at Baseline to Gr >=300
Alkaline phosphatase Gr 5 at Baseline to Gr >=300
Hypoglycemia Gr 0 at Baseline to Gr >=340
Hypoglycemia Gr 1 at Baseline to Gr >=310
Hypoglycemia Gr 2 at Baseline to Gr >=310
Hypoglycemia Gr 3 at Baseline to Gr >=300
Hypoglycemia Gr 4 at Baseline to Gr >=300
Hypoglycemia Gr 5 at Baseline to Gr >=300
Hyperglycemia Gr 0 at Baseline to Gr >=3412
Hyperglycemia Gr 1 at Baseline to Gr >=31313
Hyperglycemia Gr 2 at Baseline to Gr >=3210
Hyperglycemia Gr 3 at Baseline to Gr >=332
Hyperglycemia Gr 4 at Baseline to Gr >=300
Hyperglycemia Gr 5 at Baseline to Gr >=300
SecondaryNumber of Participants With Shift of Laboratory Parameters (Creatinine Clearance [Chronic Kidney Disease]) From Baseline Grade to Worst NCI-CTCAE Grade >=3

NCI-CTCAE version 4.03 was used to determine Gr, where Gr refers to severity of AE: Gr 1: mild; asymptomatic/mild symptoms; Gr 2: moderate; minimal; Gr 3: severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Creatinine Clearance(Chronic kidney disease) were based on: Gr 1: estimated glomerular filtration rate (eGFR) or creatinine clearance (CrCl) \<LLN-60ml/min/1.73 m\^2; Gr2: eGFR or CrCl 59-30 ml/min/1.73 m\^2; Gr3: eGFR or CrCl 29-15 ml/min/1.73 m\^2; Gr4: eGFR or CrCl \<15 ml/min/1.73 m\^2; Gr5: Death.

Time frame:
From Baseline up to 30 days after last dose of study drug (maximum duration: up to 10 years)
Reported as:
Count of participants · Participants
Number of Participants With Shift of Laboratory Parameters (Creatinine Clearance [Chronic Kidney Disease]) From Baseline Grade to Worst NCI-CTCAE Grade >=3
ParticipantsNeoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)
Creatinine Clearance Gr 0 at Baseline to Gr >=30
Creatinine Clearance Gr 1 at Baseline to Gr >=30
Creatinine Clearance Gr 2 at Baseline to Gr >=30
Creatinine Clearance Gr 3 at Baseline to Gr >=30
Creatinine Clearance Gr 4 at Baseline to Gr >=30
Creatinine Clearance Gr 5 at Baseline to Gr >=30

Adverse events

Collected over AE data was collected from the time of signed informed consent to 30 days following the last administration of study treatment (maximum duration: up to 10 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Surgery + Adjuvant Chemotherapy (SC)91/264 (34.5%)57/195 (29.2%)141/195 (72.3%)
Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)78/266 (29.3%)102/241 (42.3%)201/241 (83.4%)
Most frequent serious events
Showing 10 of 96
Most frequent serious events
EventSurgery + Adjuvant Chemotherapy (SC)Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)
Febrile NeutropeniaBlood and lymphatic system disorders0/19521/241
Abdominal PainGastrointestinal disorders6/19512/241
EnteritisGastrointestinal disorders6/1954/241
IleusGastrointestinal disorders6/1954/241
DiarrhoeaGastrointestinal disorders4/1955/241
Mechanical IleusGastrointestinal disorders4/1950/241
PyrexiaGeneral disorders2/1954/241
Decreased AppetiteMetabolism and nutrition disorders1/1954/241
Gastrointestinal Anastomotic LeakInjury, poisoning and procedural complications3/1951/241
EnterocolitisGastrointestinal disorders1/1953/241
Most frequent other events
Showing 10 of 23
Most frequent other events
EventSurgery + Adjuvant Chemotherapy (SC)Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)
AlopeciaSkin and subcutaneous tissue disorders7/195117/241
DyspepsiaGastrointestinal disorders43/19565/241
Skin HyperpigmentationSkin and subcutaneous tissue disorders52/19549/241
Peripheral Sensory NeuropathyNervous system disorders8/19542/241
PruritusSkin and subcutaneous tissue disorders25/19537/241
MyalgiaMusculoskeletal and connective tissue disorders7/19533/241
InsomniaPsychiatric disorders12/19530/241
Lacrimation IncreasedEye disorders23/19522/241
Aspartate Aminotransferase IncreasedInvestigations21/19520/241
Alanine Aminotransferase IncreasedInvestigations20/19518/241

Baseline characteristics

Analysis was performed on Intent-to-Treat (ITT) population which included all randomized participants.

Age, Continuous
Age, Continuous(years)Surgery + Adjuvant Chemotherapy (SC)Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)Total
Mean57.28 ± 10.0957.11 ± 10.0357.19 ± 10.05
Sex: Female, Male
Sex: Female, Male(Participants)Surgery + Adjuvant Chemotherapy (SC)Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)Total
Female5059109
Male214207421
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Surgery + Adjuvant Chemotherapy (SC)Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)Total
Count of participants——0
08

Study locations

1 site
  • Administrative Office
    Seoul, Korea, Republic of
09

References and documents

Publications

  • Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, Ryu MH, Rha SY, Chung IJ, Kim IH, Oh SC, Park YS, Son T, Jung MR, Heo MH, Kim HK, Park C, Yoo CH, Choi JH, Zang DY, Jang YJ, Sul JY, Kim JG, Kim BS, Beom SH, Cho SH, Ryu SW, Kook MC, Ryoo BY, Kim HK, Yoo MW, Lee NS, Lee SH, Kim G, Lee Y, Lee JH, Noh SH. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol. 2021 Sep 10;39(26):2903-2913. doi: 10.1200/JCO.20.02914. Epub 2021 Jun 16. PubMed 34133211 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2011 to primary completion in Jan 2019, 84 months.

Results were first posted in Mar 2020, 1 year 1 month after primary completion.

Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's 84 months is above that.

Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2012
First posted
Jan 24, 2012
StartActual
Dec 30, 2011
Primary completionActual
Jan 21, 2019
CompletionActual
Dec 13, 2021
Results first posted
Mar 2, 2020
Last update
Dec 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01515748
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jan 24, 2012
Start date
Dec 30, 2011
Primary completion
Jan 21, 2019
Completion
Dec 13, 2021
Results posted
Mar 2, 2020
Last update
Dec 13, 2023

Study contacts

Yoon-Koo KANG, MD, PhD
principal investigator · Asan Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Oxaliplatin

Start the discussion